Publications by authors named "Satoyo Otsuka"
Background/aim: Upper gastrointestinal obstruction is an extremely rare complication of primary ovarian cancer. We present a case of primary advanced ovarian cancer with gastroduodenal obstruction successfully managed with neoadjuvant chemotherapy (NAC) and conservative treatment.
Case Report: A 60-year-old woman was referred to our hospital for advanced ovarian cancer with upper gastrointestinal obstruction.
Objective: Therapy-related myeloid neoplasms (t-MNs) are often fatal and arise as late complications of previous anticancer drug treatment. No single-center case series has examined t-MNs in epithelial ovarian cancer (EOC).
Methods: All patients with EOC treated at Chiba University Hospital between 2000 and 2021 were included.
Several cancers harbor "enhancer-type" mutations of the telomerase reverse transcriptase (TERT) promoter for immortalization. Here, we report that 8.6% (8/93) of ovarian clear cell carcinomas (OCCCs) possess the "suppressor-type" TERT promoter mutation.
View Article and Find Full Text PDFArticle Synopsis
- The Japan Society of Obstetrics and Gynecology organized "Welcome to OBGYN World!" (WOW!) to address a decline in doctors specializing in obstetrics and gynecology, particularly targeting lower-grade medical students.
- The event was held online to ensure safety during the COVID-19 pandemic and involved participation from 60 of 82 medical schools in Japan, with 285 students and 106 tutors engaged.
- Post-event feedback revealed that a significant majority of participants (97.6%) developed a strong interest in the specialty, while all tutors acknowledged the event's effectiveness in recruitment, leading to plans for an annual WOW! event.
Background: We evaluated whether the serum hormone levels are useful in the differential diagnosis of granulosa cell tumors (GCTs), regardless of menopausal status. Methods: Serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, estradiol, and progesterone were measured preoperatively in all patients (n = 471) who underwent surgery for ovarian tumors at Chiba University Hospital between 2009 and 2021. These were compared in two groups, a GCT group (n = 13) and a group with other histological types (non-GCT) (n = 458).
View Article and Find Full Text PDFBackground/aim: The 2014 International Federation of Gynecology and Obstetrics (FIGO) classification subdivides patients with stage IIIA1 ovarian, fallopian tube, and peritoneal cancers by the greatest dimension of metastatic lymph node without supporting evidence. This study aimed to assess the validity of this subdivision.
Patients And Methods: A retrospective single-institution cohort study was performed in patients with ovarian, fallopian tube, or peritoneal cancer from 2009 to 2020.
Article Synopsis
- - The study looked at the impact of highly aggressive surgery on survival and complications in 209 patients with advanced ovarian cancer (stage III/IV) who received complex surgeries from 2008 to 2018.
- - Patients were divided into two groups based on the complexity of their surgery: less aggressive (SCS 8-12) and highly aggressive (SCS ≥13), with no significant differences in overall survival or postoperative complications between the two.
- - The findings suggest that while highly aggressive surgery does not markedly improve survival or reduce complications, it may still benefit suitable patients through proper selection and timing of surgery.
Introduction: The aim of the study was to evaluate the influence of estradiol-producing ovarian tumors, including surface epithelial-stromal tumors, on the cervical cytology of postmenopausal women.
Methods: This case-controlled study included 160 postmenopausal women who underwent a gynecological surgery between January 2009 and December 2016. The relationship between serum estradiol levels and the maturation index of cervical cytology was examined.
Background/aim: Brain metastases from ovarian cancer remain rare and the appropriate treatment is unknown. We investigated survival outcomes following salvage chemotherapy before and after bevacizumab approval to evaluate the efficacy of bevacizumab in patients with brain metastasis from ovarian cancer.
Patients And Methods: We investigated 23 consecutive patients with brain metastasis from ovarian cancer at our hospital between 2001 and 2020.
Objective: Splenectomy with or without distal pancreatectomy is occasionally performed during cytoreductive surgery for advanced ovarian cancer. We investigated pre-, intra-, postoperative risk factors and predictors of clinically relevant postoperative pancreatic fistula (CR-POPF) in patients who underwent cytoreductive surgery for advanced ovarian cancer.
Methods: We investigated 165 consecutive patients with ovarian, fallopian tube, and peritoneal carcinoma categorized as stage III/IV disease, who underwent splenectomy with or without distal pancreatectomy as a component of cytoreductive surgery performed as initial treatment at Chiba University Hospital.
Extended colon resection is often performed in advanced ovarian cancer. Restoring intestinal continuity and avoiding stoma creation improve patients' quality of life postoperatively. We tried to minimize the number of anastomoses, restore intestinal continuity, and avoid stoma creation for 295 patients with stage III/IV ovarian cancer who underwent low anterior rectal resection (LAR) with or without colon resection during cytoreductive surgery.
View Article and Find Full Text PDF(1) Background: We investigated survival outcomes following first-line chemotherapy before and after approval of bevacizumab (Bev) for ovarian cancer in Japan to evaluate the efficacy of Bev for advanced clear cell carcinoma (CCC). (2) Methods: We investigated 28 consecutive patients diagnosed with CCC (stages III/IV) at our hospital between 2008 and 2018. Bev was administered for treatment of advanced CCC after approval in Japan in November 2013.
View Article and Find Full Text PDFBackground: To investigate whether rectosigmoid colectomy can improve the prognosis of patients with early-stage ovarian cancer when the ovarian tumor adheres to the rectum.
Methods: We retrospectively studied 210 consecutive patients with stage I/II ovarian cancer treated between 2000 and 2016. The surgical strategy differed between the periods 2000-2007 and 2008-2016 with respect to adhesion between the ovarian tumor and rectum.
Article Synopsis
- This study evaluated the safety and effectiveness of a weekly chemotherapy regimen (paclitaxel and cisplatin) in ovarian cancer patients who had an allergic reaction to carboplatin.
- Researchers reviewed data from 86 patients who experienced carboplatin hypersensitivity during prior treatments and analyzed their responses to the new regimen over several cycles.
- Results showed that the majority of patients tolerated the new chemotherapy well, with median progression-free and overall survival times of 10.9 months and 25.9 months, respectively.
Objective: We investigated the efficacy and toxicity of tailored-dose chemotherapy with gemcitabine and irinotecan for platinum-refractory/resistant ovarian or primary peritoneal cancer.
Methods: We enrolled patients with ovarian or primary peritoneal cancer who received ≥2 previous chemotherapeutic regimens but developed progressive disease during platinum-based chemotherapy or within 6 months post-treatment. All patients received gemcitabine (500 mg/m²) and irinotecan (50 mg/m²) on days 1 and 8 every 21 days at the starting dose.